Global Autotransfusion Devices Market Report and Forecast 2024-2032

Global Autotransfusion Devices Market Outlook

The global autotransfusion devices market size attained a value of USD 297.26 million in 2023, driven by developing healthcare infrastructure, rapid diagnosis of diseases, rising incidences of haemorrhage, increasing need for safe and sufficient medical procedures, availability of different types of autotransfusion systems and their exceptional benefits. The market is anticipated to grow at a CAGR of 5.0% during the forecast period of 2024-2032 to attain a value of USD 461.14 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Demand for Intraoperative Autotransfusion Systems to Propel the Market Growth of Autotransfusion Devices

Based on product type, the demand for intraoperative transfusion systems is witnessing a healthy growth. The intraoperative autotransfusion systems enable the collection of a patient's own blood during a surgery or an invasive procedure where the blood loss can be anticipated or unpredictable. The washed red blood cells are then transfused back to the patient’s body after the removal of discarded products like platelets and anticoagulants. It decreases net perioperative blood loss, helps maintain postoperative haemoglobin, reduces the risk of blood-borne diseases, reduces patient care costs, eliminates the risk of receiving wrong blood due to human or clerical error, and helps recycle lost blood products. Moreover, the patient's own fresh red blood cells are known to maintain their flexibility in the microcirculation, thereby becoming immediately active in tissue oxygenation. The government initiatives towards developing national frameworks that would maximise patient safety during intraoperative autotransfusion are likely to bolster the autotransfusion devices market growth over the forecast period.

Market Segmentation

Autotransfusion devices refer to equipment that helps in the autotransfusion of blood, including the offering of autologous blood to a patient during surgical or invasive procedures. The autologous blood is collected from a patient during heavy blood loss, and the washed red blood cells are re-infused into the body. The autotransfusion of blood is safe, cost-effective, and reduces the dependency on allogenic blood.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The market for autotransfusion devices, by product type, is divided into:

• Autotransfusion Systems
  • Intraoperative Autotransfusion Systems
  • Post-Operative Autotransfusion Systems
  • Dual-Mode Autotransfusion Systems
• Consumables and Accessories

Based on application, the market is segmented into:

• Cardiovascular Surgeries
• Orthopaedic Surgeries
• Neurological Surgeries
• Obstetrics and Gynaecology Surgeries
• Others

On the basis of end-use, the market is classified into:

• Hospitals
• Speciality Clinics
• Others

The regional markets for autotransfusion devices can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Surgeries and the Exceptional Benefits of the Devices to Drive the Market Growth of Autotransfusion Devices

The increasing number of surgeries conducted worldwide, owing to the developing healthcare infrastructure and the rapid diagnosis of diseases, leads to the increased demand for blood for performing these procedures, which is driving the autotransfusion devices market growth. The rising incidences of haemorrhage and the increasing need for safe and sufficient blood and blood products to save lives are propelling the demand for these devices. The autotransfusion of blood offers multiple advantages over donated blood, such as it is cost-effective, does not lose its fluidity and function during storage, reduces the risk of infections and complications, eliminates the dependency on blood bank reserves, and reduces morbidity rate. Additionally, it is considered a safe procedure, owing to the advancements in filtration and sterile techniques. The availability of different types of autotransfusion systems, such as in-line, self-filling, and continuous, is aiding the market development. Continuous autotransfusion is faster, requires less staffing involvement, and poses a reduced risk of contamination. The strong presence of autotransfusion device manufacturers and their initiatives to launch sophisticated, effective, and automated devices are expected to augment the market growth over the forecast period.

Key Players in the Global Market for Autotransfusion Devices

The report gives a detailed analysis of the following key players in the global autotransfusion devices market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• LivaNova PLC
• Haemonetics Corporation
• Medtronic plc
• Fresenius SE & Co. KGaA
• Becton, Dickinson, and Company (BD)
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report